Communicating the value of new products to payers and providers, in today's crowded market

17 April 2017

In this week's Expert View, Gijs Hubben considers the role of value communication in facilitating market access for new pharmaceuticals, distilling his experience into three key recommendations for engagement with payers and providers.

Dr Hubben is chief executive and co-founder of software company BaseCase. Since 2007, he has partnered with life science companies to develop value communication tools using his company's proprietary customer engagement platform.

The life sciences industry has long been challenged by increasing budget pressures worldwide, an increasingly competitive marketplace and steadily decreasing face time with customers. In the struggle to attract the scarce attention and budget of payers and healthcare providers, value communication has become paramount and is now a crucial element of any product launch.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK